Hostname: page-component-7c8c6479df-24hb2 Total loading time: 0 Render date: 2024-03-28T12:36:26.669Z Has data issue: false hasContentIssue false

Commentary on: L-Methylfolate, Methylcobolamine, and N-Acetylcysteine in the Treatment of Alzheimer's Disease-Related Cognitive Decline

Published online by Cambridge University Press:  07 November 2014

Extract

Drs. McCaddon and Hudson provide a thorough review of the multiple ways in which vitamin B12, vitamin B6, folate, and homocysteine (Hey) are implicated in the pathogenesis of Alzheimer's disease (AD). They noted that Hey is more often elevated in AD and in mild cognitive impairment (MCI) than in cognitively healthy elderly; phosphatases needed to limit tau hyperphosphoryalation and neurofibrillary tangle formation require methylation and are dependent on folate and methylation status; cerebrospinal fluid (CSF) tau levels correlated with markers of methylation status; reduced folate and B12 levels lead to increase β-secretase and pesenilin 1 (PS1) actions leading to greater amyloid-β production in in vitro models; elevated Hey levels in rates are associated with increased PS1 activity and spatial memory deficits that are reversed following treatment with B12 and folate; raised Hey levels in vitro increase amyloid-β protein neurotoxicity; methylation impacts transmitters and transmitter function relevant to AD; in cultured neurons, Hey induces injury in DNA and stimulates cell death pathways. B12 deficiency leads to accumulation of methyl malonic acid, which inhibits mitochondrial function and may compromise energy generation and impair maintenance of synaptic plasticity. Methylation abnormalities result in excessive generation of reactive oxygen species that contribute importantly to cell injury. Biomarkers of oxidative injury, such as isoprostanes, are elevated in AD and suggest excess oxidation. Thus, there are multiple pathways through which deficient methylation may contribute to AD. In some cases, the observations are derived from models with B12 or folate deficiency and some in vitro observations have not been tested in in vivo models. There are no biomarkers specific to some of the pathways implicated and the magnitude of the impact of the deficiency or its treatment has not been established for all the relationships. Two open-label experiments in early- and late-stage AD patients have suggested benefit.

Type
Expert Review Supplement
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Seshadri, S, Beiser, A, Selhub, J, et al.Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. New Engl J Med. 2002;346:476483.CrossRefGoogle ScholarPubMed
2.Serot, JM, Christmann, D, Dubost, T, Bene, MC, Faure, GC. CSF-folate levels are decreased in late-onset AD patients. J Neural Transm. 2001;108:9399.CrossRefGoogle ScholarPubMed
3.Durga, J, von Boxtel, MPJ, Schouten, EG, et al.Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomized double-blind, controlled trial. Lancet. 2007;369:208216.CrossRefGoogle Scholar
4.Aisen, PS, Schneider, LS, Diaz-Arrastia, R, et al.High-dose vitamin B supplementation and cognitive decline in Alzheimer's disease. JAMA. 2008;300:17741783.CrossRefGoogle Scholar